Memantine and Comprehensive, Individualized Management of Alzheimer's Disease and Caregiver Training
Completed
Fisher Center for Alzheimer's Research Foundation
Phase 4
2006-08-01
The purpose of this study is to determine whether a comprehensive, individualized management
approach with caregiver training and medication with memantine will alleviate symptoms in
community dwelling patients with moderate to severe Alzheimer's disease.
Memantine and Comprehensive, Individualized Management of Alzheimer's Disease and Caregiver Training
Completed
Forest Laboratories
Phase 4
2006-08-01
The purpose of this study is to determine whether a comprehensive, individualized management
approach with caregiver training and medication with memantine will alleviate symptoms in
community dwelling patients with moderate to severe Alzheimer's disease.
Memantine and Comprehensive, Individualized Management of Alzheimer's Disease and Caregiver Training
Completed
New York University School of Medicine
Phase 4
2006-08-01
The purpose of this study is to determine whether a comprehensive, individualized management
approach with caregiver training and medication with memantine will alleviate symptoms in
community dwelling patients with moderate to severe Alzheimer's disease.
Memantine and Comprehensive, Individualized Management of Alzheimer's Disease and Caregiver Training
Completed
NYU Langone Health
Phase 4
2006-08-01
The purpose of this study is to determine whether a comprehensive, individualized management
approach with caregiver training and medication with memantine will alleviate symptoms in
community dwelling patients with moderate to severe Alzheimer's disease.
Neuropsychiatric manifestations of Systemic Lupus Erythematosus (NPSLE) are both common and
an important source of morbidity. Of the case definitions for NPSLE syndromes that have
recently been developed, cognitive dysfunction appears to be the most prevalent. A novel
mechanism is that a subset of SLE patients with cognitive dysfunction have antibodies in the
NR2 glutamate receptor. We propose, in a double -blind placebo-controlled trial, to determine
whether SLE patients, with or without the NR2 glutamate receptor antibody, have significant
improvement using memantine, an inhibitor of the NMDA receptor.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
